Bausch Health Companies (BHC) Cost of Revenue (2009 - 2026)

Bausch Health Companies has disclosed Cost of Revenue across 18 years of filings, most recently posting $753.0 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 0.67% year-over-year to $753.0 million; the TTM figure through Jun 2026 stood at $3.0 billion (up 5.95% YoY), while the FY2025 annual figure was $2.9 billion, up 8.06% from the prior year.
• Cost of Revenue came in at $753.0 million for Q2 2026 at Bausch Health Companies, up from $721.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $783.0 million in Q4 2025 to a low of $536.0 million in Q1 2022.
• Average Cost of Revenue over 5 years is $665.9 million, with a median of $682.5 million recorded in 2024.
• Year-over-year, Cost of Revenue slipped 5.96% in 2022 and gained 12.68% in 2023.
• Over 5 years, Cost of Revenue stood at $639.0 million in 2022, then climbed by 8.76% to $695.0 million in 2023, then rose by 2.3% to $711.0 million in 2024, then rose by 10.13% to $783.0 million in 2025, then declined by 3.83% to $753.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $753.0 million in Q2 2026, $721.0 million in Q1 2026, and $783.0 million in Q4 2025.